Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | BioCentury Commentary

Big thinkers

Pharma mega-mergers — a look back at the rationale behind the Glaxo-SmithKline tie-up: BioCentury’s 30th anniversary collection

By BioCentury Staff
February 7, 2023 12:30 AM UTC

What goes around, comes around. In a December 2022 episode of BioCentury This Week, in-coming GSK CSO Tony Wood described a genomics tapestry that he would be weaving to recreate the pharma’s erstwhile oncology franchise.

Almost a quarter-century ago, BioCentury examined the underpinnings of the anticipated merger of Glaxo Welcome and SmithKline Beecham, where the protagonists aimed to create a research behemoth in the age of genomics. It was the first of a series of “Big Thinkers” reviews of big pharma’s mostly failed attempts to create value via peer-to-peer M&A. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Gsk plc